Showing 1 to 5 of 5 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma
I244 NCT05998642  Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Non-Hodgkin's Lymphoma |
Dr. Jean-François Larouche Philippe Nadeau 418-649-0252 poste 63115 |
|
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
BGB-16673-101 NCT05006716 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Non-Hodgkin's Lymphoma |
Dr. Olivier Dumas Maryse Gingras 418-525-4444 poste 15781 |
|
A Randomized Phase 3 Trial of Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
COG-ANHL1931 NCT04759586 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
CHUL ET CENTRE MERE-ENFANT SOLEIL
|
Non-Hodgkin's Lymphoma |
Dr. Bruno Michon |
|
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma
EPCORE FL-1 NCT05409066 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Non-Hodgkin's Lymphoma |
Dr. Jean-François Larouche Philippe Nadeau 418-649-0252 poste 63115 |
|
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma
OLYMPIA-1 NCT06091254 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Non-Hodgkin's Lymphoma |
Dr. Christopher Lemieux Philippe Nadeau 418-649-0252 poste 63115 |
Groupe d'étude en oncologie du Québec